Dysport – the new Botox competitor from Ipsen and Medicis Pharmaceutical – just received FDA approval for treating wrinkles and dystonia. Plastic surgeons and dermatologists expect to have the drug available in about 30 days.

Although Medicis had planned to rebrand the product as ‘Reloxin’, they ultimately decided to retain its original European name, Dysport. (pronounced Diss-port).

Botox and Dysport both perform the same basic function – neuromuscular blocking to relax and prevent wrinkles. Dysport is said to be more diluted than Botox and perhaps, more cost effective for providers.

The April 30th announcement coincided with a 3 percent drop in Allergan’s (maker of Botox) shares, as Medicis shares jumped 14 percent. Analysts and industry professionals expect Dysport to carry a slightly lower price tag than Botox, and speculate that it may capture 30 percent of the market.